Advertisement

Topics

Vernalis Company Profile

20:27 EDT 19th September 2017 | BioPortfolio

Vernalis is a UK-based specialty pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat migraine. The company has a broad development pipeline focused on neurology and central nervous system disorders.

Location

Oakdene Court
613 Reading Road
Winnersh
Surrey
RG41 5UA
United Kingdom

Contact

Phone: +44 (0)118 977 3133
Fax: +44 (0)118 989 9300


News Articles [22 Associated News Articles listed on BioPortfolio]

Vernalis shares slide after latest FDA rejection

Shares in UK pharma Vernalis slid more than 15% after the US regulator rejected its cough and cold treatment, known as CCP-08. The FDA sent Vernalis a dreaded Complete Response Letter (CRL) rejectin...

#news #biotech Back-to-back FDA rejections leave Vernalis reeling

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Back-to-back FDA rejections leave Vernalis reeling .The FDA has rejected Vern...

FDA Rejects Second Vernalis Cough/Cold Candidate

Vernalis acknowledged today that its New Drug Application (NDA) for CCP-08 has been rejected by the FDA—the second time in four months that the agency has turned down applications by the company for...

FDA Rejects Second Vernalis Cough Cold Candidate

Vernalis acknowledged today that its New Drug Application (NDA) for CCP-08 has been rejected by the FDA—the second time in four months that the agency has turned down applications by the company for...

Vernalis plc: Results Announcement for the year ended 30 June 2017

WINNERSH, UNITED KINGDOM--(Marketwired - Sep 12, 2017) - Vernalis PLC ( LSE : VER) ( OTC PINK : VNLPY) 12 September 2017 LSE: Read more...

Vernalis stopped cold: US FDA rejects cough medicine NDA

The US FDA has rejected Vernalis’ new drug application for its investigative cough and cold treatment CCP-08, which is the second time the firm has failed to win approval for a product this year.  

Vernalis cough and cold drug knocked-back by FDA

Vernalis has been given a second CRL for a cough and cold treatment by the FDA this year. The therapy, known as CCP-08, has fallen foul of the issues that led to CCP-07 being rejected earlier this yea...

FDA rejects second Vernalis cough/cold treatment

The US Food and Drug Administration has rejected Vernalis’ cough cold treatment CCP-08, which is being developed by US partner Tris Pharma.

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Vernalis

Vernalis is a UK-based specialty pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat m...

More Information about "Vernalis" on BioPortfolio

We have published hundreds of Vernalis news stories on BioPortfolio along with dozens of Vernalis Clinical Trials and PubMed Articles about Vernalis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Vernalis Companies in our database. You can also find out about relevant Vernalis Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...


Corporate Database Quicklinks



Searches Linking to this Company Record